drug · oligonucleotide
patient view →eplontersen sodium
Marketedupdated 2mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Approvedcommunity read0 votes
Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for familial amyloid neuropathy and polyneuropathy and 1 investigational indication.
targets
Transthyretin mRNA
all catalysts(5)
approval · 5
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that